Q1 Earnings Estimate for VTGN Issued By William Blair

Vistagen Therapeutics, Inc. (NASDAQ:VTGN - Free Report) - Research analysts at William Blair issued their Q1 2026 EPS estimates for shares of Vistagen Therapeutics in a research note issued to investors on Thursday, November 7th. William Blair analyst M. Minter anticipates that the company will post earnings per share of ($0.36) for the quarter. William Blair has a "Strong-Buy" rating on the stock. The consensus estimate for Vistagen Therapeutics' current full-year earnings is ($1.79) per share. William Blair also issued estimates for Vistagen Therapeutics' Q2 2026 earnings at ($0.38) EPS, Q3 2026 earnings at ($0.35) EPS and Q4 2026 earnings at ($0.34) EPS.

Vistagen Therapeutics Stock Down 3.8 %

Shares of NASDAQ VTGN traded down $0.12 during trading on Monday, reaching $3.02. 180,200 shares of the company traded hands, compared to its average volume of 191,209. Vistagen Therapeutics has a 52-week low of $2.55 and a 52-week high of $5.86. The stock has a market capitalization of $81.72 million, a PE ratio of -2.53 and a beta of 0.78. The firm has a 50 day simple moving average of $3.09 and a 200-day simple moving average of $3.54.

Vistagen Therapeutics (NASDAQ:VTGN - Get Free Report) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.41) by $0.06. The firm had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.30 million. Vistagen Therapeutics had a negative net margin of 4,521.71% and a negative return on equity of 34.67%. During the same quarter last year, the firm posted ($0.94) EPS.

Institutional Investors Weigh In On Vistagen Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. StemPoint Capital LP increased its position in Vistagen Therapeutics by 3.3% in the first quarter. StemPoint Capital LP now owns 1,848,582 shares of the company's stock worth $9,292,000 after purchasing an additional 58,400 shares during the last quarter. Acadian Asset Management LLC purchased a new position in Vistagen Therapeutics during the first quarter worth $169,000. Blair William & Co. IL boosted its stake in Vistagen Therapeutics by 29.2% during the second quarter. Blair William & Co. IL now owns 88,466 shares of the company's stock worth $308,000 after buying an additional 20,000 shares during the period. Finally, American Century Companies Inc. boosted its stake in Vistagen Therapeutics by 49.1% during the second quarter. American Century Companies Inc. now owns 30,315 shares of the company's stock worth $105,000 after buying an additional 9,984 shares during the period. Institutional investors own 78.39% of the company's stock.

Vistagen Therapeutics Company Profile

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.